A structural biology view of target drugability

Expert Opinion on Drug Discovery

Volumn 3, Issue 4, 2008, Pages 391-401

  Egner, Ursula ^a   Hillig, Roman C ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Drugability prediction; Structural biology; Structural target assessment

Indexed keywords

AMINOPYRIDINE DERIVATIVE; ANGIOPOIETIN RECEPTOR; ASPARAGINE; BLOOD CLOTTING FACTOR 10A; CYCLIN DEPENDENT KINASE 2; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; GLUTAMINE; HORMONE RECEPTOR; ION CHANNEL; PHOSPHATASE; PROLINE; PROTEIN MDM2; PROTEINASE; RAF PROTEIN; SORAFENIB; SULFATE;

ACCURACY; BINDING AFFINITY; BINDING SITE; BIOINFORMATICS; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG INDUSTRY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; ENZYME STRUCTURE; HUMAN; HYDROPHOBICITY; INFORMATION RETRIEVAL; MACHINE LEARNING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN DATA BANK; PROTEIN FAMILY; REVIEW; SUPPORT VECTOR MACHINE;

EID: 42949151886     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.4.391     Document Type: Review

References (67)

1. Bains W. Failure rates in drug discovery and development: will we ever get any better? Drug Discov World 2004:9-18
2. Drews J. Research & development. Basic science and pharmaceutical innovation. Nat Biotechnol 1999;17(5):406
3. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1(9):727-30
4. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006;5(10):821-34
5. Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34(Database issue):D668-72
6. Zheng CJ, Han LY, Yap CW, et al. Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol Rev 2006;58(2):259-79
7. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993-6
8. Chen X, Ji ZL, Chen YZ. TTD: Therapeutic Target Database. Nucleic Acids Res 2002;30(1):412-5
9. Paolini GV, Shapland RH, van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol 2006;24(7):805-15
10. Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today 2005;10(23-24):1607-10
11. Sakharkar MK, Sakharkar KR, Pervaiz S. Druggability of human disease genes. Int J Biochem Cell Biol 2007;39(6):1156-64
12. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44(1):235-49
13. Han LY, Zheng CJ, Xie B, et al. Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness. Drug Discov Today 2007;12(7-8):304-13
14. Hopkins AL, Groom CR. Target analysis: a priori assessment of druggability. Ernst Schering Res Found Workshop 2003;(42):11-7
15. Keller TH, Pichota A, Yin Z. A practical view of'druggability'. Curr Opin Chem Biol 2006;10(4):357-61
16. Zheng C, Han L, Yap CW, et al. Progress and problems in the exploration of therapeutic targets. Drug Discov Today 2006;11(9-10):412-20
17. Meisner NC, Hintersteiner M, Uhl V, et al. The chemical hunt for the identification of drugable targets. Curr Opin Chem Biol 2004;8(4):424-31
18. Egner U, Kratzschmar J, Kreft B, et al. The target discovery process. Chembiochem 2005;6(3):468-79
19. Hajduk PJ, Huth JR, Tse C. Predicting protein druggability. Drug Discov Today 2005;10(23-24):1675-82
20. Leach AR, Hann MM, Burrows JN, Griffen EJ. Fragment screening: an introduction. Mol Biosyst 2006;2(9):430-46
21. Schade M. NMR fragment screening: advantages and applications. IDrugs 2006;9(2):110-3
22. Schuffenhauer A, Ruedisser S, Marzinzik AL, et al. Library design for fragment based screening. Curr Top Med Chem 2005;5(8):751-62
23. Hajduk PJ, Huth JR, Fesik SW. Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 2005;48(7):2518-25
24. Yuan Z, Burrage K, Mattick JS. Prediction of protein solvent accessibility using support vector machines. Proteins 2002;48(3):566-70
25. Hasan S, Daugelat S, Rao PS, Schreiber M. Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput Biol 2006;2(6):e61
26. Li H, Gao Z, Kang L, et al. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res 2006;34(Web Server issue):W219-24
27. Hambly K, Danzer J, Muskal S, Debe DA. Interrogating the druggable genome with structural informatics. Mol Divers 2006;10(3):273-81
28. Finn RD, Mistry J, Schuster-Bockler B, et al. Pfam: clans, web tools and services. Nucleic Acids Res 2006;34(Database issue):D247-51
29. Chuaqui C, Deng Z, Singh J. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening. J Med Chem 2005;48(1):121-33
30. Deng Z, Chuaqui C, Singh J. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. J Med Chem 2004;47(2):337-44
31. Sheinerman FB, Giraud E, Laoui A. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. J Mol Biol 2005;352(5):1134-56
32. Vajda S, Guarnieri F. Characterization of protein-ligand interaction sites using experimental and computational methods. Curr Opin Drug Discov Devel 2006;9(3):354-62
33. Berman HM, Bhat TN, Bourne PE, et al. The Protein Data Bank and the challenge of structural genomics. Nat Struct Biol 2000;7(Suppl):957-9
34. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000;28(1):235-42
35. Mestres J. Representativity of target families in the Protein Data Bank: impact for family-directed structure-based drug discovery. Drug Discov Today 2005;10(23-24):1629-37
36. Holler TP, Evdokimov AG, Narasimhan L. Structural Biology approaches to antibacterial drug discovery. Expert Opin Drug Discov 2007;2(8):1085-101
37. Sinnecker S, Neese F. QM/MM calculations with DFT for taking into account protein effects on the EPR and optical spectra of metalloproteins. Plastocyanin as a case study. J Comput Chem 2006;27(12):1463-75
38. Villar R, Gil MJ, Garcia JI, Martinez-Merino V. Are AM1 ligand-protein binding enthalpies good enough for use in the rational design of new drugs? J Comput Chem 2005;26(13):1347-58
39. Laurie AT, Jackson RM. Methods for the prediction of protein-ligand binding sites for structure-based drug design and virtual ligand screening. Curr Protein Pept Sci 2006;7(5):395-406
40. Nayal M, Honig B. On the nature of cavities on protein surfaces: application to the identification of drug-binding sites. Proteins 2006;63(4):892-906
41. Bergner A, Günther J. Structural aspects of binding site similarity: a 3D upgrade for chemogenomics: WILEY-VCH Verlag GmbH & Co. KGaA. Weinheim; 2004
42. An J, Totrov M, Abagyan R. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 2005;4(6):752-61
43. Glaser F, Morris RJ, Najmanovich RJ, et al. A method for localizing ligand binding pockets in protein structures. Proteins 2006;62(2):479-88
44. Halgren T. New method for fast and accurate binding-site identification and analysis. Chem Biol Drug Des 2007;69(2):146-8
45. Kellenberger E, Muller P, Schalon C, et al. sc-PDB: an annotated database of druggable binding sites from the Protein Data Bank. J Chem Inf Model 2006;46(2):717-27
46. Golovin A, Dimitropoulos D, Oldfield T, et al. MSDsite: a database search and retrieval system for the analysis and viewing of bound ligands and active sites. Proteins 2005;58(1):190-9
47. Kinoshita K, Nakamura H. Identification of the ligand binding sites on the molecular surface of proteins. Protein Sci 2005;14(3):711-8
48. Brown SP, Hajduk PJ. Effects of conformational dynamics on predicted protein druggability. ChemMedChem 2006;1(1):70-2
49. Eyrisch S, Helms V. Transient pockets on protein surfaces involved in protein-protein interaction. J Med Chem 2007;50(15):3457-64
50. Cheng AC, Coleman RG, Smyth KT, et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 2007;25(1):71-5
51. Coleman RG, Salzberg AC, Cheng AC. Structure-based identification of small molecule binding sites using a free energy model. J Chem Inf Model 2006;46(6):2631-7
52. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 2001;46(1-3):3-26
53. Fauman EB, Hopkins AL, Groom CR. Structural bioinformatics in drug discovery. Methods Biochem Anal 2003;44:477-97
54. Proudfoot JR. The evolution of synthetic oral drug properties. Bioorg Med Chem Lett 2005;15(4):1087-90
55. Folkertsma S, van Noort PI, Brandt RF, et al. The nuclear receptor ligand-binding domain: a family-based structure analysis. Curr Med Chem 2005;12(9):1001-16
56. Mochalkin I, Lightle S, Narasimhan L, et al. Structure of a small-molecule inhibitor complexed with GlmU from Haemophilus influenzae reveals an allosteric binding site. Protein Sci 2008;17(3):577-82
57. Todd AE, Orengo CA, Thornton JM. Plasticity of enzyme active sites. Trends Biochem Sci 2002;27(8):419-26
58. Schäfer M, Egner U. Structural aspects of drugability and selectivity of protein kinases in inflammation. Anti Inflamm Anti Allergy Agents Med Chem 2007;6:5-17
59. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10(18 Pt 2):S6388-92
60. Kallen J, Lattmann R, Beerli R, et al. Crystal structure of human estrogen-related receptor {alpha} in complex with a synthetic inverse agonist reveals its novel molecular mechanism. J Biol Chem 2007;282(32):23231-9
61. Dudkina AS, Lindsley CW. Small molecule protein-protein inhibitors for the p53-MDM2 interaction. Curr Top Med Chem 2007;7(10):952-60
62. Adler M, Kochanny MJ, Ye B, et al. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. Biochemistry 2002;41(52):15514-23
63. Lucking U, Siemeister G, Schafer M, et al. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities. ChemMedChem 2007;2(1):63-77
64. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
65. Song H, Hanlon N, Brown NR, et al. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. Mol Cell 2001;7(3):615-26
66. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
67. Shewchuk LM, Hassell AM, Ellis B, et al. Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure 2000;8(11):1105-13